Melissa Geller, MD
Gynecologic Oncology · Minneapolis, MNNPI 1265466809
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,190 of the $14,274 with a category attached, or 92.4%. GSK accounts for 68.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $14,223 and has fallen 99.8% since, to $34 in 2025.
Across 9 payments — averaging $1586.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$10K
- Sanofi US Services Inc.$4K
- Merck$628
- Teleflex LLC$96
- Medtronic$34
Across 55 payments — averaging $10,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$270K
- GSK$158K
- Genentech, Inc.$108K
- Eisai Inc.$30K
- Merck$14K
What the payments were for
- Consulting fees$13,19092%
- Travel & lodging$9006%
- Food & beverage$1661%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $9,737 |
| Sanofi US Services Inc. | 1 | $3,780 |
| Merck | 2 | $628 |
| Teleflex LLC | 1 | $96 |
| Medtronic | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$610
How this compares
$14,274 in reported general payments places this provider in the 80th percentile of 39 gynecologic oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 11 | $71 |
| Fluoxetine Hcl | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Minneapolis
- Britt EricksonMinneapolis$28K
- Emily PrendergastMinneapolis$10K
- Colleen Rivard HuntMinneapolis$3K
- Sabrina BedellMinneapolis$1K
- Jordan MattsonMinneapolis$1K
- Lauren BollingerMinneapolis$355
- Deanna TeohMinneapolis$135
- Alexandra SchefterMinneapolis$77
- Sally MullanyMinneapolis$47
- Rahel GhebreMinneapolis$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.